Business Description
ResMed Inc
NAICS : 339112
SIC : 3841
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
Compare
Compare
Traded in other countries / regions
RMD.Australia
•
RMD.Austria
•
R1MD34.Brazil
•
RME.Germany
•
RMD.Mexico
•
0KW4.UK
•
RMD.USA
Description
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | 0.71 | |||||
| Interest Coverage | 44.73 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 15.58 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 16.7 | |||||
| 3-Year EPS without NRI Growth Rate | 13.9 | |||||
| 3-Year FCF Growth Rate | 12 | |||||
| 3-Year Book Growth Rate | 11.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 11.08 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.58 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.57 | |||||
| 9-Day RSI | 58.18 | |||||
| 14-Day RSI | 60.81 | |||||
| 6-1 Month Momentum % | -11.54 | |||||
| 12-1 Month Momentum % | -21.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 1.56 | |||||
| Cash Ratio | 0.3 | |||||
| Days Inventory | 127.64 | |||||
| Days Sales Outstanding | 56.71 | |||||
| Days Payable | 35.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.7 | |||||
| Dividend Payout Ratio | 0.32 | |||||
| 3-Year Dividend Growth Rate | 3.7 | |||||
| Forward Dividend Yield % | 0.73 | |||||
| 5-Year Yield-on-Cost % | 0.91 | |||||
| 3-Year Average Share Buyback Ratio | -0.7 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.29 | |||||
| Operating Margin % | 27.87 | |||||
| Net Margin % | 22.02 | |||||
| ROE % | 25.9 | |||||
| ROA % | 16.46 | |||||
| ROIC % | 20.49 | |||||
| ROC (Joel Greenblatt) % | 79.02 | |||||
| ROCE % | 24.57 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.2 | |||||
| Forward PE Ratio | 37.88 | |||||
| PE Ratio without NRI | 45.2 | |||||
| Shiller PE Ratio | 72.42 | |||||
| Price-to-Owner-Earnings | 102.12 | |||||
| PEG Ratio | 2.99 | |||||
| PS Ratio | 9.96 | |||||
| PB Ratio | 10.71 | |||||
| Price-to-Tangible-Book | 35.93 | |||||
| Price-to-Free-Cash-Flow | 102.6 | |||||
| Price-to-Operating-Cash-Flow | 70.75 | |||||
| EV-to-EBIT | 36.41 | |||||
| EV-to-Forward-EBIT | 29.09 | |||||
| EV-to-EBITDA | 30.39 | |||||
| EV-to-Forward-EBITDA | 26.23 | |||||
| EV-to-Revenue | 10.1 | |||||
| EV-to-Forward-Revenue | 8.91 | |||||
| EV-to-FCF | 104.03 | |||||
| Price-to-Projected-FCF | 3.74 | |||||
| Price-to-DCF (Earnings Based) | 2.74 | |||||
| Price-to-DCF (FCF Based) | 5.5 | |||||
| Price-to-Median-PS-Value | 1.82 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.71 | |||||
| Price-to-Graham-Number | 8.5 | |||||
| Price-to-Net-Current-Asset-Value | 452.81 | |||||
| Earnings Yield (Greenblatt) % | 2.75 | |||||
| Forward Rate of Return (Yacktman) % | 18.02 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:RMD
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,539.492 | ||
| EPS (TTM) ($) | 5.31 | ||
| Beta | 0.57 | ||
| Volatility % | 31.37 | ||
| 14-Day RSI | 60.81 | ||
| 14-Day ATR ($) | 5.723923 | ||
| 20-Day SMA ($) | 236.4725 | ||
| 12-1 Month Momentum % | -21.59 | ||
| 52-Week Range ($) | 189.4 - 301.34 | ||
| Shares Outstanding (Mil) | 146.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ResMed Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||